Review ArticleTargeting the Mevalonate Pathway for Treating Lung CancerFatehi Hassanabad, Ali MD, MSc; Mina, Fady BScAuthor Information Cumming School of Medicine, University of Calgary, Calgary, AB, Canada The authors declare no conflicts of interest. Reprints: Ali Fatehi Hassanabad, MD, MSc, Foothills Medical Centre, Cumming School of Medicine, University of Calgary, Room 880, Main Building, 1403 29th Street NW, Calgary, AB, Canada T2N 2T9. E-mail: firstname.lastname@example.org. Online date: November 2, 2019 American Journal of Clinical Oncology: January 2020 - Volume 43 - Issue 1 - p 69-70 doi: 10.1097/COC.0000000000000630 Buy Metrics Abstract The mevalonate (MVA) pathway is a key metabolic pathway involved in various important cellular functions. Its downstream products are critical for cell-signaling, cell membrane integrity, protein synthesis, and cellular respiration. The rate-limiting enzyme of this pathway is targeted by statins, a class of medications best known for their lipid-lowering effects. Many studies have shown that a variety of cancerous cells have a dysregulated MVA pathway. Lung cancer is responsible for a third of all cancer-related deaths worldwide. As our understanding of the molecular mechanisms driving the pathogenesis of lung cancer improves, newer therapeutics have been proposed. However, these medications have not had the expected benefits for all subtypes of lung cancer. Therefore, there exists a significant role in identifying medications with safe profiles, which can potentially be used in managing various types of lung cancer. Herein, we review whether there is a role in utilizing statins to target the MVA pathway in treating lung cancer. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.